For gene therapy of hemophilia A, at years 7 and 6, mean (median) FVIII activity (chromogenic substrate [CS] assay) was 16.2 (10.3) and 6.7 (7.2) IU/dL in the 6 × 1013 (n = 5) and 4 × 1013 (n = 4) cohorts, respectively, corresponding to mild hemophilia and leading to a 96% and 88% decrease of the annual bleeding rate from baseline, respectively [5]. The gene discussed is F8; the disease is hemophilia A.